T-cell activating anti-CD3 antibodies are remarkable antibodies - capable of killing a very wide range of cancers. However, their long-standing problem is that they can be too effective – causing major off-target effects. Interesting approaches to control their target specificity have been developed, including a wide range of bispecific antibodies, but there is still a very real need of employing them at high doses determined not critically only by the level of side effects but by efficacy such that tumours can be hit quickly and very hard.
The approach that Precision Immunotherapeutics takes is to make the anti-CD3 antibodies, both in their native and bispecific states, light dependent such that their activities can only be expressed when illuminated at the required site. Bringing this extra level of target-specificity to bear is aimed at opening the door to a multitude of different applications in which high doses of these excellent antibodies can be delivered safely in their ‘cloaked’ form ready for activation to achieve rapid remission, before uncontrollable mutations occur in tumours.
Company Details
- Employees
- 2
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://precisionitx.com
Precision Immunotherapeutics Ltd Questions
Precision Immunotherapeutics Ltd's website is http://precisionitx.com
Precision Immunotherapeutics Ltd's LinkedIn profile is https://www.linkedin.com/company/precision-immunotherpeutics-ltd
Precision Immunotherapeutics Ltd has
2 employees.
View email and phone details for 2
employees at Precision Immunotherapeutics Ltd.
Precision Immunotherapeutics Ltd's industry is
Biotechnology Research
Precision Immunotherapeutics Ltd's top competitors are
Bio-Innov8.com,
The Open World Technology Group,
Beacon Scientific Consulting,
Biopharma Assets,
Touch Medical Media Group Holdings,
Viveo - Science & Technology Marketing,
Bi-Path Bio, Ltd,
Caterpillar Hill Limited,
Oncolytika,
Mozeka Limited.
Precision Immunotherapeutics Ltd's categories are Biotechnology Research
Precision Immunotherapeutics Ltd's founding year is 2018
